Similar articles

• Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.

  Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Abraham NS, et al. Gastroenterology. 2017 Apr;152(5):1014-1022.e1. doi: 10.1053/j.gastro.2016.12.018. Epub 2016 Dec 30. Gastroenterology. 2017. PMID: 28043907
• Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.

  Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Noseworthy PA, et al. Chest. 2016 Dec;150(6):1302-1312. doi: 10.1016/j.chest.2016.07.013. Epub 2016 Sep 28. Chest. 2016. PMID: 27938741
• Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

  Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Lip GY, et al. J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9. J Am Coll Cardiol. 2012. PMID: 22575324
• Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.

  [No authors listed] [No authors listed] Prescrire Int. 2013 Jun;22(139):155-9. Prescrire Int. 2013. PMID: 23866358 Review.
• An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

  Mantha S, Ansell J. Mantha S, et al. Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Thromb Haemost. 2012. PMID: 22740145 Review.